Marc Goodman
Stock Analyst at Leerink Partners
(2.91)
# 1,650
Out of 4,711 analysts
100
Total ratings
54.55%
Success rate
25.45%
Average return
Main Sectors:
Stocks Rated by Marc Goodman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLMD Relmada Therapeutics | Downgrades: Market Perform | $10 → $1 | $0.36 | +175.56% | 3 | Dec 4, 2024 | |
| BHVN Biohaven | Maintains: Outperform | $55 → $60 | $36.26 | +65.47% | 6 | Sep 23, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Outperform | $32 | $32.63 | -1.93% | 1 | Apr 15, 2024 | |
| AMLX Amylyx Pharmaceuticals | Downgrades: Market Perform | n/a | $4.05 | - | 4 | Mar 11, 2024 | |
| BLTE Belite Bio | Initiates: Outperform | $25 | $64.12 | -61.01% | 1 | Jul 26, 2023 | |
| DNLI Denali Therapeutics | Initiates: Outperform | $50 | $21.45 | +133.10% | 1 | Jan 30, 2023 | |
| MRNS Marinus Pharmaceuticals | Maintains: Outperform | $27 → $23 | $0.23 | +9,900.00% | 4 | Jan 23, 2023 | |
| EOLS Evolus | Maintains: Outperform | $18 → $20 | $10.89 | +83.65% | 3 | Jan 19, 2023 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $65 → $85 | $90.73 | -6.32% | 6 | Nov 29, 2022 | |
| NBIX Neurocrine Biosciences | Maintains: Market Perform | $100 → $115 | $135.42 | -15.08% | 4 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $270 → $310 | $146.47 | +111.65% | 11 | Oct 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $12 | $10.31 | +16.39% | 2 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $46 | $38.63 | +19.08% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $21 | $16.87 | +24.48% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $200 → $210 | $122.97 | +70.77% | 5 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $50 → $40 | $5.61 | +613.01% | 5 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $2.68 | +273.13% | 2 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $24 → $27 | $29.71 | -9.12% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $3.34 | +648.48% | 1 | Apr 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $70 | $83.45 | -16.12% | 3 | Apr 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $15 | $4.88 | +207.38% | 2 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $270 | $430.01 | -37.21% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $79 → $96 | $175.58 | -45.32% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $57.33 | - | 2 | May 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $67 | $98.05 | -31.67% | 3 | Oct 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $98 | $25.75 | +280.58% | 7 | Oct 5, 2017 |
Relmada Therapeutics
Dec 4, 2024
Downgrades: Market Perform
Price Target: $10 → $1
Current: $0.36
Upside: +175.56%
Biohaven
Sep 23, 2024
Maintains: Outperform
Price Target: $55 → $60
Current: $36.26
Upside: +65.47%
LENZ Therapeutics
Apr 15, 2024
Initiates: Outperform
Price Target: $32
Current: $32.63
Upside: -1.93%
Amylyx Pharmaceuticals
Mar 11, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $4.05
Upside: -
Belite Bio
Jul 26, 2023
Initiates: Outperform
Price Target: $25
Current: $64.12
Upside: -61.01%
Denali Therapeutics
Jan 30, 2023
Initiates: Outperform
Price Target: $50
Current: $21.45
Upside: +133.10%
Marinus Pharmaceuticals
Jan 23, 2023
Maintains: Outperform
Price Target: $27 → $23
Current: $0.23
Upside: +9,900.00%
Evolus
Jan 19, 2023
Maintains: Outperform
Price Target: $18 → $20
Current: $10.89
Upside: +83.65%
Axsome Therapeutics
Nov 29, 2022
Maintains: Outperform
Price Target: $65 → $85
Current: $90.73
Upside: -6.32%
Neurocrine Biosciences
Nov 2, 2022
Maintains: Market Perform
Price Target: $100 → $115
Current: $135.42
Upside: -15.08%
Oct 26, 2022
Maintains: Outperform
Price Target: $270 → $310
Current: $146.47
Upside: +111.65%
Aug 11, 2022
Maintains: Outperform
Price Target: $6 → $12
Current: $10.31
Upside: +16.39%
Aug 11, 2022
Maintains: Outperform
Price Target: $40 → $46
Current: $38.63
Upside: +19.08%
Aug 9, 2022
Maintains: Outperform
Price Target: $27 → $21
Current: $16.87
Upside: +24.48%
Aug 4, 2022
Maintains: Outperform
Price Target: $200 → $210
Current: $122.97
Upside: +70.77%
Jul 11, 2022
Maintains: Market Perform
Price Target: $50 → $40
Current: $5.61
Upside: +613.01%
Jul 11, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $2.68
Upside: +273.13%
Apr 28, 2022
Maintains: Market Perform
Price Target: $24 → $27
Current: $29.71
Upside: -9.12%
Apr 26, 2022
Initiates: Outperform
Price Target: $25
Current: $3.34
Upside: +648.48%
Apr 21, 2022
Maintains: Outperform
Price Target: $65 → $70
Current: $83.45
Upside: -16.12%
Dec 21, 2021
Maintains: Outperform
Price Target: $24 → $15
Current: $4.88
Upside: +207.38%
Mar 13, 2020
Maintains: Buy
Price Target: $300 → $270
Current: $430.01
Upside: -37.21%
Nov 19, 2019
Maintains: Buy
Price Target: $79 → $96
Current: $175.58
Upside: -45.32%
May 21, 2018
Downgrades: Neutral
Price Target: n/a
Current: $57.33
Upside: -
Oct 30, 2017
Maintains: Buy
Price Target: $72 → $67
Current: $98.05
Upside: -31.67%
Oct 5, 2017
Maintains: Buy
Price Target: $84 → $98
Current: $25.75
Upside: +280.58%